These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 24740119)

  • 1. The prognostic significance of proliferative indices in surgically resected IIIA-N2 non-small cell lung cancer after induction chemotherapy.
    Corzani R; Luzzi L; Spina D; Voltolini L; Paladini P; Ghiribelli C; Ghisalberti M; Borrelli R; Meniconi F; Monaci N; Gotti G
    J Cardiovasc Surg (Torino); 2017 Oct; 58(5):763-769. PubMed ID: 24740119
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Outcome of Patients With pN2 "Potentially Resectable" Nonsmall Cell Lung Cancer Who Underwent Surgery After Induction Chemotherapy.
    Spaggiari L; Casiraghi M; Guarize J; Brambilla D; Petrella F; Maisonneuve P; De Marinis F
    Semin Thorac Cardiovasc Surg; 2016 Summer; 28(2):593-602. PubMed ID: 28043483
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Outcomes and prognostic factors of non-small-cell lung cancer with lymph node involvement treated with induction treatment and surgical resection.
    Marulli G; Verderi E; Zuin A; Schiavon M; Battistella L; Perissinotto E; Romanello P; Favaretto AG; Pasello G; Rea F
    Interact Cardiovasc Thorac Surg; 2014 Aug; 19(2):256-62; discussion 262. PubMed ID: 24824495
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mediastinal downstaging after induction treatment is not a significant prognostic factor to select patients who would benefit from surgery: the clinical value of the lymph node ratio.
    Renaud S; Falcoz PE; Olland A; Reeb J; Santelmo N; Massard G
    Interact Cardiovasc Thorac Surg; 2015 Feb; 20(2):222-7. PubMed ID: 25413781
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Induction chemoradiotherapy is superior to induction chemotherapy for the survival of non-small-cell lung cancer patients with pathological mediastinal lymph node metastasis.
    Toyooka S; Kiura K; Shien K; Katsui K; Hotta K; Kanazawa S; Date H; Miyoshi S
    Interact Cardiovasc Thorac Surg; 2012 Dec; 15(6):954-60. PubMed ID: 22976995
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic Factors for Surgically Resected N2 Non-small Cell Lung Cancer.
    Kawasaki K; Sato Y; Suzuki Y; Saito H; Nomura Y; Yoshida Y
    Ann Thorac Cardiovasc Surg; 2015; 21(3):217-22. PubMed ID: 25641029
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic factors after complete resection of pN2 non-small cell lung cancer.
    Sonobe M; Date H; Wada H; Okubo K; Hamakawa H; Teramukai S; Matsumura A; Nakagawa T; Sumitomo S; Miyamoto Y; Okumura N; Takeo S; Kawakami K; Aoki M; Kosaka S;
    J Thorac Cardiovasc Surg; 2013 Oct; 146(4):788-95. PubMed ID: 23810113
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Surgical multimodality treatment for baseline resectable stage IIIA-N2 non-small cell lung cancer. Degree of mediastinal lymph node involvement and impact on survival.
    Decaluwé H; De Leyn P; Vansteenkiste J; Dooms C; Van Raemdonck D; Nafteux P; Coosemans W; Lerut T
    Eur J Cardiothorac Surg; 2009 Sep; 36(3):433-9. PubMed ID: 19502079
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Analysis of Patients Unable to Undergo Adjuvant Chemotherapy after Surgery in Stage IIIA/B Non-Small Cell Lung Cancer: Will They Benefit from Mediastinal Radiotherapy?
    Graeter TP; Sebastian B; Bischof M; Kugler G; Fischer JR; Schneider T
    Thorac Cardiovasc Surg; 2016 Sep; 64(6):501-6. PubMed ID: 26322832
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Validation of pN2 sub-classifications in patients with pathological stage IIIA N2 non-small cell lung cancer.
    Nakagiri T; Sawabata N; Funaki S; Inoue M; Kadota Y; Shintani Y; Okumura M
    Interact Cardiovasc Thorac Surg; 2011 May; 12(5):733-8. PubMed ID: 21297135
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Surgery for patients with persistent pathological N2 IIIA stage in non-small-cell lung cancer after induction radio-chemotherapy: the microscopic seed of doubt.
    Meacci E; Cesario A; Cusumano G; Lococo F; D'Angelillo R; Dall'armi V; Margaritora S; Granone P
    Eur J Cardiothorac Surg; 2011 Sep; 40(3):656-63. PubMed ID: 21402479
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Survival of patients with clinical stage IIIA non-small cell lung cancer after induction therapy: age, mediastinal downstaging, and extent of pulmonary resection as independent predictors.
    Paul S; Mirza F; Port JL; Lee PC; Stiles BM; Kansler AL; Altorki NK
    J Thorac Cardiovasc Surg; 2011 Jan; 141(1):48-58. PubMed ID: 21092990
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combined treatment modalities in Pancoast tumor: results of a monocentric retrospective study.
    Jeannin G; Merle P; Janicot H; Thibonnier L; Kwiatkowski F; Naame A; Chadeyras JB; Galvaing G; Belliere A; Filaire M; Verrelle P
    Chin Clin Oncol; 2015 Dec; 4(4):39. PubMed ID: 26730751
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The impact of residual multi-level N2 disease after induction therapy for non-small cell lung cancer.
    Sawabata N; Keller SM; Matsumura A; Kawashima O; Hirono T; Osaka Y; Maeda H; Fukai S; Kawahara M;
    Lung Cancer; 2003 Oct; 42(1):69-77. PubMed ID: 14512190
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic Significance of the Number of Metastatic pN2 Lymph Nodes in Stage IIIA-N2 Non-Small-Cell Lung Cancer After Curative Resection.
    Yoo C; Yoon S; Lee DH; Park SI; Kim DK; Kim YH; Kim HR; Choi SH; Kim WS; Choi CM; Jang SJ; Song SY; Kim SS; Choi EK; Lee JC; Suh C; Lee JS; Kim SW
    Clin Lung Cancer; 2015 Nov; 16(6):e203-12. PubMed ID: 25997733
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A prognostic score system with lymph node ratio in stage IIIA-N2 NSCLC patients after surgery and adjuvant chemotherapy.
    Han H; Zhao Y; Gao Z; Zheng D; Fu F; Zhao Z; Tang Y; Xiang J; Sun Y; Hu H; Chen H
    J Cancer Res Clin Oncol; 2019 Aug; 145(8):2115-2122. PubMed ID: 31175463
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nodal stage after induction therapy for stage IIIA lung cancer determines patient survival.
    Bueno R; Richards WG; Swanson SJ; Jaklitsch MT; Lukanich JM; Mentzer SJ; Sugarbaker DJ
    Ann Thorac Surg; 2000 Dec; 70(6):1826-31. PubMed ID: 11156079
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lymphatic invasion predicts survival in patients with early node-negative non-small cell lung cancer.
    Nentwich MF; Bohn BA; Uzunoglu FG; Reeh M; Quaas A; Grob TJ; Perez D; Kutup A; Bockhorn M; Izbicki JR; Vashist YK
    J Thorac Cardiovasc Surg; 2013 Oct; 146(4):781-7. PubMed ID: 23778087
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Is neoadjuvant chemotherapy mandatory for limited-disease small-cell lung cancer?
    Xu YJ; Zheng H; Gao W; Jiang GN; Xie HK; Chen C; Fei K
    Interact Cardiovasc Thorac Surg; 2014 Dec; 19(6):887-93. PubMed ID: 25156899
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Post-recurrence survival of patients with non-small-cell lung cancer after curative resection with or without induction/adjuvant chemotherapy.
    Saisho S; Yasuda K; Maeda A; Yukawa T; Okita R; Hirami Y; Shimizu K; Nakata M
    Interact Cardiovasc Thorac Surg; 2013 Feb; 16(2):166-72. PubMed ID: 23143203
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.